Journals / Mikrobiyoloji Bülteni / 2005 / Cilt: 39 - Sayı: 2

Extended-spectrum beta lactamases: Their role in clinical microbiology laboratory, treatment and infection control

Genişlemiş spektrumlu beta laktamazlar: Klinik mikrobiyoloji laboratuvarı, tedavi ve enfeksiyon kontrolündeki rolleri

Pages
229–240
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review article, the roles of ESBL in clinical microbiology laboratory, treatment and infection control, have been discussed.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The major mechanism responsible for resistance to p-lactam antibiotics is the production of (3-lactamases.
📊
Key Findings & Data:Recently, more than 150 ESBLs have been identified.
💡
Conclusion & Impact:In this review article, the roles of ESBL in clinical microbiology laboratory, treatment and infection control, have been discussed.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Epidemiyoloji · beta-Laktamazlar · Epidemiology

Abstract

The major mechanism responsible for resistance to p-lactam antibiotics is the production of (3-lactamases. These enzymes, which have the ability to inactivate extended-spectrum p-lactam antibiotics, like cefotaxime and ceftazidime are called as extended-spectrum p-lactamases (ESBL). The most important pathogen which produces p-lactamases among Gram positive bacteria is Staphylococcus aureus and the members of the Enterobacteriaceae family are the leading p-lactamase producing organisms among Gram negative bacteria. Although the p-lactamase inhibitors like clavulanic acid, sulbactam and tazobactam could block ESBL effects, ESBL's have still been considered as a threat since they are coded by plasmids and can easily be transmitted between species. Recently, more than 150 ESBLs have been identified. Numerous methods have been proposed for the detection of ESBLs in clinical isolates. Imipenem seems to be the most effective agent for the therapy and control of the spread of infections caused by ESBL-producing bacteria. In this review article, the roles of ESBL in clinical microbiology laboratory, treatment and infection control, have been discussed.

Özet

Beta-laktam halkası içeren antimikrobiyal ajanlara karşı gelişen direnç mekanizmalarının başında p-laktamaz enzimlerinin üretimi gelmektedir. Sefotaksim ve seftazidim gibi genişlemiş spektrumlu p-laktam ajanları inaktive edebilme yeteneğindekı enzimler "genişlemiş spektrumlu p-laktamaz" (extended spectrum p-lactamases: ESBL) olarak adlandırılmaktadır. Gram pozitif bakteriler içinde p-laktamaz sentezleyen en önemli patojen Staphylococcus aureus iken, Gram negatifler arasında ilk sırayı Enterobacteriaceae ailesinin üyeleri almaktadır. Klavulanik asit, sulbaktam ve tazobaktam gibi p-laktamaz inhibitörleri, ESBL etkisini bloke edebilmekle birlikte, ESBL'lerin sıklıkla plazmidler üzerinde kodlanmaları ve bu nedenle suşlar arasında kolaylıkla yayılmaları büyük sorun oluşturmaktadır. Bugün 150'nin üzerinde farklı ESBL tanımlanmıştır. ESBL üreten klinik izolatları saptamak için çok sayıda metod önerilmektedir. ESBL taşıyan ajanlar ile oluşan enfeksiyonların yayılmasını önlemede ve tedavide en etkili ajan imipenem olarak görünmektedir. Bu derleme yazıda, ESBL'lerin klinik mikrobiyoloji laboratuvarı, tedavi ve enfeksiyon kontrolündeki rolleri tartışılmaktadır.

🔖

Cite This Article

DOLAPÇI, G. İ. (2005). Extended-spectrum beta lactamases: Their role in clinical microbiology laboratory, treatment and infection control. Mikrobiyoloji Bülteni, Cilt: 39 - Sayı: 2, 229–240. https://ajindex.com/articles/299051

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Gülay Z: Antimikrobiyal ilaçlara Direnç, s: 91-108, Ustaçelebi Ş (ed), Klinik Mikrobiyoloji Kitabı.1999, Güneş Kitabevi, Ankara
  2. Knox JR: Extended-spectrum and inhibitor-resistant TEM-type |3-lactamases: Mutations, specificity,and three-dimensional structure. Antimicrob Agents Chemother 1995, 39: 2593-2601
  3. Morris D, O'Hare C, Glennon M, Maher M, Corbett-Feeney G, Cormican M: Extended-spectrum 3-lactamases in Ireland, including a novel enzyme, TEM-102. Antimicrob Agents Chemother 2003,47: 2572-2578
  4. Gniadkowski M: Evolution and epidemiology of extended-spectrum p-lactamases (ESBLs) and ESBL-producing microorganisms. Clin Microbiol Infect 2001, 7: 596-608
  5. Gür D: Bakterilerde Antibiyotiklere Karşı Direnç, s: 182-191, Topçu AW, Söyletir G, Doğanay M (ed),İnfeksiyon Hastalıkları ve Mikrobiyoloji Kitabı. Cilt 1, 2. baskı. 2002, Nobel Tıp Kitabevi, İstanbul
  6. Rupp ME, Fey PD: Extended spectrum beta lactamase (ESBL)-producing Enterobacteriaceae:Considerations for diagnosis, prevention and drug treatment. Drugs 2003, 63: 353-365
  7. Bodey GP: Beta-lactam resistance today and tomorrow: A global issue, p: 4-11. In: Inoue M (ed),Issues and Answers in Beta-Lactam Resistance. Proceedings from the First Net Care Meeting, Monte Carlo. October 1999 (Clinical Monograph S). Cambridge Medical Publications, West Sussex, UK
  8. Kim YK, Pai H, Lee HJ, et al: Bloodstream infections by extended-spectrum p-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: Epidemiology and clinical outcome. Antimicrob Agents Chemother 2002, 46: 1481-1491
  9. Akata F, Tatman-Otkun M, Özkan E, Tansel O, Otkun M, Tuğrul M: Prevalence of extended-spectrum beta-lactamases produced by nosocomial isolates of Enterobacteriaceae in Trakya University Hospital, Turkey. New Microbiol 2003, 26: 257-262
  10. Sturenburg E, Mack D: Extended-spectrum beta-lactamases: Implications for the clinical microbiology laboratory, therapy, and infection control. J Infect 2003, 47: 273-295
  11. Bradford PA: Extended-spectrum p-lactamases in the 21 st century: Characterization, epidemiology,and detection of this important resistance threat. Clin Microbiol Rev 2001, 14: 933-951
  12. Rolinson GN: Forty years of p-lactam research. J Antimicrob Chemother 1998, 41: 589-603
  13. Akova M: Regional differences in beta-lactam resistance, p: 12-21. In: Inoue M (ed), Issues and Answers in Beta-Lactam Resistance. Proceedings from the First Net Care Meeting, Monte Carlo. October 1999 (Clinical M